Dermatology

The Pharmacy Times® Dermatology resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
Top news of the day across the health care landscape.
[[thumbnail_alt_text]]
A phase 3 trial evaluated dupilumab (Dupixent, Regeneron and Sanofi) in children from 6 to 11 years of age with severe atopic dermatitis.
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
[[thumbnail_alt_text]]
Patients with psoriasis reported frequent use of complementary and alternative treatments when their initial therapies did not help or had adverse effects.
[[thumbnail_alt_text]]
The study focused on the comparative risk of infection across 7 systemic biologics.
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
[[thumbnail_alt_text]]
A head-to-head trial evaluated quality of life improvements in patients with moderate-to-severe psoriasis treated with secukinumab (Cosentyx) or ustekinumab (Stelara).
[[thumbnail_alt_text]]
Top news of the week from Specialty Pharmacy Times.
[[thumbnail_alt_text]]
With this approval, dupilumab (Dupixent) offers a biologic therapy option for patients 12 to 17 years of age who have moderate-to-severe atopic dermatitis.
[[thumbnail_alt_text]]
Approximately 1.7 million insured US patients are burdened with moderate to severe plaque psoriasis.
[[thumbnail_alt_text]]
Tildrakizumab was approved by the FDA as a subcutaneous therapy for patients with moderate-to-severe psoriasis.
+ Load More